Opinion: dealing with failure, iTeos style
When your investment case breaks down, why not just do the decent thing?
When your investment case breaks down, why not just do the decent thing?
Suzhou Zelgen’s DLL3 x DLL3 project looks better than regular T-cell engagers, with caveats.
The company sees an improvement with a Tecvayli/Talvey combo vs either monotherapy.
The players are vying in the CD19 x CD20 Car-T arena.
INCA033989 looks potent in essential thrombocythemia, but already the opportunity looks tiny.
The Enliven molecule looks competitive against Scemblix, triggering a $200m raise.
Casdatifan might have found its sweet spot, as part of a Cabometyx combo.
The move follows promising but early data presented at ASCO.